PMID- 20605615
OWN - NLM
STAT- MEDLINE
DCOM- 20110106
LR  - 20221207
IS  - 1532-8600 (Electronic)
IS  - 0026-0495 (Linking)
VI  - 60
IP  - 1
DP  - 2011 Jan
TI  - Vaspin and visfatin/Nampt are interesting interrelated adipokines playing a role 
      in the pathogenesis of type 2 diabetes mellitus.
PG  - 63-70
LID - 10.1016/j.metabol.2010.04.008 [doi]
AB  - Recently, vaspin and visfatin/Nampt have been identified as interesting novel 
      adipokines having insulin-sensitizing and insulin-mimetic effects, respectively. 
      However, the relationship between them has not been elucidated; and their 
      circulating levels in type 2 diabetes mellitus (T2DM) have not been adequately 
      studied. Therefore, this study was designed to investigate whether their levels 
      are altered in Egyptian T2DM patients and to study the correlation of these novel 
      adipokines with each other and with insulin resistance, interleukin-6 (IL-6), and 
      other biochemical parameters. The levels of vaspin, visfatin/Nampt, IL-6, 
      insulin, and other parameters were measured in nonobese and obese T2DM patients 
      together with matched healthy nondiabetic control subjects. Vaspin, 
      visfatin/Nampt, and IL-6 levels were measured by enzyme-linked immunosorbent 
      assay, whereas insulin levels were measured by chemiluminescence technique. 
      Vaspin and visfatin/Nampt levels were found to be significantly elevated in 
      nonobese (1.62 +/- 0.22 and 25.9 +/- 3.44 ng/mL, respectively) and obese T2DM 
      patients (2.76 +/- 0.38 and 45.4 +/- 4.60 ng/mL, respectively) compared with control 
      subjects (0.42 +/- 0.05 and 9.37 +/- 1.98 ng/mL, respectively) at P < .01. In 
      addition, vaspin and visfatin/Nampt levels were found to be significantly 
      positively correlated with each other and with other biochemical parameters. In 
      conclusion, both vaspin and visfatin/Nampt might play an important role in the 
      pathogenesis of T2DM. In addition, the 3 adipokines--vaspin, visfatin/Nampt, and 
      IL-6--are significantly interrelated with each other. Other possible mechanisms 
      of action for vaspin should be considered besides the inhibition of unknown 
      substrate proteases.
CI  - Copyright (c) 2011 Elsevier Inc. All rights reserved.
FAU - El-Mesallamy, Hala O
AU  - El-Mesallamy HO
AD  - Faculty of Pharmacy, Biochemistry Department, Ain Shams University, Abbassia, 
      11566 Cairo, Egypt.
FAU - Kassem, Dina H
AU  - Kassem DH
FAU - El-Demerdash, Ebtehal
AU  - El-Demerdash E
FAU - Amin, Ashraf I
AU  - Amin AI
LA  - eng
PT  - Journal Article
DEP - 20100601
PL  - United States
TA  - Metabolism
JT  - Metabolism: clinical and experimental
JID - 0375267
RN  - 0 (Blood Glucose)
RN  - 0 (Cytokines)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Interleukin-6)
RN  - 0 (Lipids)
RN  - 0 (SERPINA12 protein, human)
RN  - 0 (Serpins)
RN  - 0 (hemoglobin A1c protein, human)
RN  - EC 2.4.2.12 (Nicotinamide Phosphoribosyltransferase)
RN  - EC 2.4.2.12 (nicotinamide phosphoribosyltransferase, human)
SB  - IM
MH  - Blood Glucose/analysis
MH  - Body Mass Index
MH  - Cytokines/*physiology
MH  - Diabetes Mellitus, Type 2/*etiology
MH  - Female
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Insulin Resistance
MH  - Interleukin-6/blood
MH  - Lipids/blood
MH  - Male
MH  - Middle Aged
MH  - Nicotinamide Phosphoribosyltransferase/*physiology
MH  - Serpins/*physiology
EDAT- 2010/07/08 06:00
MHDA- 2011/01/07 06:00
CRDT- 2010/07/08 06:00
PHST- 2010/01/06 00:00 [received]
PHST- 2010/03/21 00:00 [revised]
PHST- 2010/04/09 00:00 [accepted]
PHST- 2010/07/08 06:00 [entrez]
PHST- 2010/07/08 06:00 [pubmed]
PHST- 2011/01/07 06:00 [medline]
AID - S0026-0495(10)00127-7 [pii]
AID - 10.1016/j.metabol.2010.04.008 [doi]
PST - ppublish
SO  - Metabolism. 2011 Jan;60(1):63-70. doi: 10.1016/j.metabol.2010.04.008. Epub 2010 
      Jun 1.